Effect of etanercept on iritis in patients with ankylosing spondylitis [5]

Arthritis and Rheumatism

Volumn 50, Issue 11, 2004, Pages 3736-3737

  Rosenbaum, James T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HLA B27 ANTIGEN; PLACEBO; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; BEHCET DISEASE; CLINICAL TRIAL; EYE INFLAMMATION; HUMAN; IRITIS; JUVENILE RHEUMATOID ARTHRITIS; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; UVEITIS;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IRITIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING;

EID: 8444244864     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20754     Document Type: Letter

References (11)

1. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
2. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
3. Mease PJ, Goffe BS, Metz J, VanderSteop A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: randomised trial. Lancet 2000;356:385-90.
4. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7.
5. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol 2003;87:925.
6. Kaipiainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumor necrosis factor a inhibitors. Ann Rheum Dis 2003;62:88-9.
7. Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis [letter]. Arth Rheum 2003;48: 2079-80.
8. Smith JA, Smith S, Whitcup SM, Suhler E, Clarke G, Thompson D, et al. The treatment of JRA-associated uveitis with etanercept [abstract]. Arthritis Rheum 2002;46 Suppl 9:S482.
9. Melikoglu M, Ozyazgan Y, Fresko I, Mat C, Yurdakal S, Hamuryudan V, et al. The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-α blocker, etanercept: an open study [abstract]. Arthritis Rheum 2002;46 Suppl 9:S181.
10. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;12:437-40.
11. Calin A, Dijkmans B, Emery P, Hakala M, Kalden J, Leirisalo M, et al. Assessments of disease activity and functionality by enbreltreated ankylosing spondylitis patients in a multicenter, placebo-controlled trial [abstract]. Arthritis Rheum 2003;48 Suppl 9:S172.